RXRX vs. SDGR, RCUS, RLAY, PTCT, KYMR, RGEN, HALO, EXEL, KRYS, and CRSP
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Schrödinger (SDGR), Arcus Biosciences (RCUS), Relay Therapeutics (RLAY), PTC Therapeutics (PTCT), Kymera Therapeutics (KYMR), Repligen (RGEN), Halozyme Therapeutics (HALO), Exelixis (EXEL), Krystal Biotech (KRYS), and CRISPR Therapeutics (CRSP). These companies are all part of the "medical" sector.
Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.
Recursion Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
Schrödinger has a net margin of -75.94% compared to Recursion Pharmaceuticals' net margin of -765.90%. Schrödinger's return on equity of -29.25% beat Recursion Pharmaceuticals' return on equity.
Schrödinger has higher revenue and earnings than Recursion Pharmaceuticals. Schrödinger is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of Schrödinger shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Recursion Pharmaceuticals currently has a consensus target price of $13.00, suggesting a potential upside of 55.13%. Schrödinger has a consensus target price of $38.90, suggesting a potential upside of 74.67%. Given Schrödinger's stronger consensus rating and higher possible upside, analysts plainly believe Schrödinger is more favorable than Recursion Pharmaceuticals.
Schrödinger received 28 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 56.67% of users gave Schrödinger an outperform vote while only 53.49% of users gave Recursion Pharmaceuticals an outperform vote.
In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Schrödinger. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 10 mentions for Schrödinger. Recursion Pharmaceuticals' average media sentiment score of 0.55 beat Schrödinger's score of 0.33 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.
Summary
Schrödinger beats Recursion Pharmaceuticals on 12 of the 19 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
Free RXRX Stock Alerts